GNCA Genocea Biosciences Inc.

1.7
+0.04  (+2%)
Previous Close 1.66
Open 1.7
Price To Book 1.93
Market Cap 46,994,414
Shares 27,643,773
Volume 113,340
Short Ratio
Av. Daily Volume 293,108
Stock charts supplied by TradingView

NewsSee all news

  1. GENOCEA BIOSCIENCES, INC. (FormPRE 14A) (0001457612-20-000037)

  2. GENOCEA BIOSCIENCES, INC. Changes to Beneficial Ownership: Duvall Diantha (CHIEF FINANCIAL OFFICER) (Form4) (0001457612-20-000025)

  3. Genocea to Present at the Cowen & Company 40th Annual Health Care Conference

    CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president

  4. Genocea to Present at the SVB Leerink 9th Annual Global Healthcare Conference

    CAMBRIDGE, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president

  5. Genocea Provides Fourth Quarter 2019 Corporate Update

    ATLASTM identifies Inhibigenstm that can undermine immunotherapyDosed first patient in Part B of GEN-009 neoantigen vaccine Phase 1/2a trialProgressed GEN-011 neoantigen cell therapy - IND filing expected in Q2

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Topline data did not meet endpoints - September 2015
GEN-004
Universal vaccine candidate against pneumococcus
Phase 1/2 data due 2Q/3Q 2020
GEN-009 vaccine
Various cancers

Latest News

  1. GENOCEA BIOSCIENCES, INC. (FormPRE 14A) (0001457612-20-000037)

  2. GENOCEA BIOSCIENCES, INC. Changes to Beneficial Ownership: Duvall Diantha (CHIEF FINANCIAL OFFICER) (Form4) (0001457612-20-000025)

  3. Genocea to Present at the Cowen & Company 40th Annual Health Care Conference

    CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president

  4. Genocea to Present at the SVB Leerink 9th Annual Global Healthcare Conference

    CAMBRIDGE, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president

  5. Genocea Provides Fourth Quarter 2019 Corporate Update

    ATLASTM identifies Inhibigenstm that can undermine immunotherapyDosed first patient in Part B of GEN-009 neoantigen vaccine Phase 1/2a trialProgressed GEN-011 neoantigen cell therapy - IND filing expected in Q2

  6. Genocea to Host Fourth Quarter 2019 Corporate Update Conference Call & Webcast

    CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2019

  7. Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors

    Entrepreneurial leader brings expertise growing biotech platform companies as former CEO of Editas Medicine and Avila Therapeutics Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new

  8. Genocea to Present at the Stifel 2019 Healthcare Conference

    CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president

  9. Genocea Preclinical Data at SITC Demonstrate that Inhibitory Neoantigens in an Otherwise Protective Vaccine Reverse Anti-Tumor Responses

    ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccination Inhibitory T cell responses exacerbate tumor growth CAMBRIDGE, Mass., Nov. 09, 2019 (GLOBE

  10. Genocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society for Immunotherapy of Cancer (SITC)

        Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy Confirm positive GEN-009 clinical immunogenicity results

  11. Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference

    Additional positive GEN-009 clinical immunogenicity data driven by ATLAS™ to be presented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE

  12. Genocea to Present at September Healthcare Conferences

    CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and